Related Experiment Video
Updated: Feb 21, 2026
Xenograft Skin Model to Manipulate Human Immune Responses In Vivo
Published on: June 29, 2022
Xenograft as In Vivo Experimental Model
Manuela Porru1, Luca Pompili1,2, Carla Caruso2
1Experimental Chemotherapy Laboratory, UOSD SAFU, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy.
Abstract:
The identification of experimental models that recapitulate human cancers designed to predict patient clinical response to therapies is a major break in oncology. Cancer stem cells (CSCs) represent a small tumor cell population responsible for drug resistance, where their effective killing may lead to identifying better treatment options. While the CSCs hypothesis highlights the need for a specific tumor target, patient-derived xenografts (PDXs) should also be considered for drug development as they better represent tumor heterogeneity and the environment in which a tumor develops.
Insights
Identifying effective cancer models is crucial for predicting treatment response. Cancer stem cells (CSCs) drive drug resistance, and patient-derived xenografts (PDXs) offer better tumor representation for drug development.
Area of Science:
- Oncology
- Cancer Research
- Translational Medicine
Background:
- Predicting patient response to cancer therapies requires accurate experimental models.
- Cancer stem cells (CSCs) are implicated in therapeutic resistance.
- Tumor heterogeneity and microenvironment are critical factors in cancer progression.
Purpose of the Study:
- To highlight the importance of experimental models in oncology.
- To discuss the role of cancer stem cells in drug resistance.
- To emphasize the value of patient-derived xenografts (PDXs) in drug development.
Main Methods:
- Review of current literature on cancer models.
- Discussion of cancer stem cell biology.
- Analysis of patient-derived xenograft models.
Main Results:
- Experimental models that mimic human cancers are essential for predicting clinical response.
- Targeting cancer stem cells (CSCs) may offer new therapeutic strategies.
- Patient-derived xenografts (PDXs) provide a more comprehensive representation of tumor heterogeneity.
Conclusions:
- The development of predictive experimental cancer models is a significant challenge in oncology.
- Effective targeting of cancer stem cells is a promising avenue for overcoming drug resistance.
- Patient-derived xenografts (PDXs) are valuable tools for preclinical cancer drug development due to their ability to recapitulate tumor complexity.
